Stock Performance - Liquidia Technologies Inc (LQDA) shares rallied 5 7% in the last trading session closing at $13 62 driven by higher trading volume compared to a typical session [1] - The stock has gained 12 7% over the past four weeks [1] Product Development - The stock price rise is likely due to anticipation of final FDA approval and launch of Yutrepia (treprostinil) inhalation powder in 2025 which received temporary FDA approval in 2023 [2] - Yutrepia is indicated for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease [2] Financial Expectations - The company is expected to post a quarterly loss of $0 39 per share representing a year-over-year improvement of +7 1% [3] - Revenues are expected to be $5 13 million up 13 2% from the year-ago quarter [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days [4] Industry Comparison - Liquidia Technologies is part of the Zacks Medical - Biomedical and Genetics industry [4] - Puma Biotech (PBYI) another stock in the same industry closed the last trading session 0 3% higher at $2 98 and has returned 5 7% in the past month [4] - For Puma Biotech the consensus EPS estimate for the upcoming report has changed +50% over the past month to $0 14 representing a change of -54 8% from the year-ago quarter [5] Stock Ratings - Liquidia Technologies currently carries a Zacks Rank 2 (Buy) [4] - Puma Biotech currently has a Zacks Rank of 3 (Hold) [5]

MORRISVILLE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, beginning at approximately 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California. Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/inves ...

Liquidia Technologies, Inc. (LQDA) closed the last trading session at $10.94, gaining 6.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.44 indicates a 132.5% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $4.90. While the lowest estimate of $17 indicates a 55.4% increase from the current price level, the most optimisti ...

Liquidia Technologies, Inc. (LQDA) closed the last trading session at $11.25, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.44 indicates a 126.1% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $4.90. While the lowest estimate of $17 indicates a 51.1% increase from the current price level, the most optimistic ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.I have recently covered United Therapeutics ( UTHR ) in a note for Seeking Alpha, so I thought this would be a good time to follow up with some coverage of one of United's ...

Liquidia Corporation (NASDAQ:LQDA) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Michael Kaseta - Chief Operating Officer & Chief Financial Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG Jason Gerberry - Bank of America Greg Harrison - Scotiabank Kambiz Yazdi - Jefferies Cor ...

Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.37 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.37, delivering a surprise of -5.71%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Liquidia Technologies, wh ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) 85-1710962 (I.R.S. Employ ...

Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) · U.S. Supreme Court rejected final appeal of '793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appeal · Strengthen ...

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appealStrengthened balance sheet by raising approximately $100 million in additional capital MORRISVILLE, N.C., Nov. 13, 2024 (GLOBE ...